US EditionPublished • loading... • Updated
Novartis Can Complete Regulus Transfer
Summary by Handelszeitung
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Novartis successfully completed the acquisition of the US biotech company Regulus Therapeutics. As the Group announced on Wednesday, it was offered 74.49 percent of the outstanding shares at the end of the offer period that has now expired.
Peanut Allergy Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Stallergenes Greer, Roche and Novartis, DBV Technologies, Novartis, ALK-Abello, Aravax, InnoUp Farma, Intrommune Therapeutics
Press release - DelveInsight Business Research - Peanut Allergy Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
